Damora Therapeutics (DMRA) Cash & Equivalents Growth (1y) (2020 - 2026)

Damora Therapeutics (DMRA) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 23.81%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 15.53%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 90.42%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 17.50%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -4.13%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 71.81%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Damora Therapeutics 1.01 Bn 807.71 Mn - 3,280.03%

Historic Data

Download Data
DateValue
Mar 31, 2026 3,280.03%
Dec 31, 2025 1,717.45%
Sep 30, 2025 -61.39%
Jun 30, 2025 -19.81%
Mar 31, 2025 -71.61%
Dec 31, 2024 -43.96%
Sep 30, 2024 -50.69%
Jun 30, 2024 -44.53%
Mar 31, 2024 -15.86%
Dec 31, 2023 -22.85%
Sep 30, 2023 -34.22%
Jun 30, 2023 -70.44%
Mar 31, 2023 -44.77%
Dec 31, 2022 -47.60%
Sep 30, 2022 -8.19%
Jun 30, 2022 13.14%
Mar 31, 2022 -38.87%
Dec 31, 2021 -61.75%
Sep 30, 2021 -22.47%
Jun 30, 2021 91.50%